Literature DB >> 21893545

Therapeutic vaccines for chronic diseases: successes and technical challenges.

Martin F Bachmann1, Gary T Jennings.   

Abstract

Chronic, non-communicable diseases are the major cause of death and disability worldwide and have replaced infectious diseases as the major burden of society in large parts of the world. Despite the complexity of chronic diseases, relatively few predisposing risk factors have been identified by the World Health Organization. Those include smoking, alcohol abuse, obesity, high cholesterol and high blood pressure as the cause of many of these chronic conditions. Here, we discuss several examples of vaccines that target these risk factors with the aim of preventing the associated diseases and some of the challenges they face.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21893545      PMCID: PMC3146783          DOI: 10.1098/rstb.2011.0103

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  42 in total

1.  The world health report 2002 - reducing risks, promoting healthy life.

Authors:  J J Guilbert
Journal:  Educ Health (Abingdon)       Date:  2003-07

2.  A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats.

Authors:  P R Pentel; D H Malin; S Ennifar; Y Hieda; D E Keyler; J R Lake; J R Milstein; L E Basham; R T Coy; J W Moon; R Naso; A Fattom
Journal:  Pharmacol Biochem Behav       Date:  2000-01-01       Impact factor: 3.533

Review 3.  Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension.

Authors:  M Burnier
Journal:  Blood Press Monit       Date:  2000       Impact factor: 1.444

4.  Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response.

Authors:  Baidong Hou; Philippe Saudan; Gary Ott; Matthew L Wheeler; Ming Ji; Lili Kuzmich; Linda M Lee; Robert L Coffman; Martin F Bachmann; Anthony L DeFranco
Journal:  Immunity       Date:  2011-02-25       Impact factor: 31.745

5.  Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain.

Authors:  Y Hieda; D E Keyler; S Ennifar; A Fattom; P R Pentel
Journal:  Int J Immunopharmacol       Date:  2000-10

6.  Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8.

Authors:  Florian Heil; Hiroaki Hemmi; Hubertus Hochrein; Franziska Ampenberger; Carsten Kirschning; Shizuo Akira; Grayson Lipford; Hermann Wagner; Stefan Bauer
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

7.  Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls.

Authors:  Vendhan Gajalakshmi; Richard Peto; Thanjavur Santhanakrishna Kanaka; Prabhat Jha
Journal:  Lancet       Date:  2003-08-16       Impact factor: 79.321

8.  Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers.

Authors:  Deon M Harvey; Sevil Yasar; Stephen J Heishman; Leigh V Panlilio; Jack E Henningfield; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

9.  Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects.

Authors:  Morris J Brown; John Coltart; Kulasiri Gunewardena; James M Ritter; Timothy R Auton; James F Glover
Journal:  Clin Sci (Lond)       Date:  2004-08       Impact factor: 6.124

Review 10.  The economic impact of hypertension.

Authors:  William J Elliott
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 May-Jun       Impact factor: 3.738

View more
  26 in total

Review 1.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

2.  Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo.

Authors:  Lingjun Zhang; Wen Qiu; Stephen Crooke; Yan Li; Areeba Abid; Bin Xu; M G Finn; Feng Lin
Journal:  ACS Chem Biol       Date:  2017-01-12       Impact factor: 5.100

3.  Vaccines and future global health needs.

Authors:  G J V Nossal
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

4.  Twenty-first century vaccines.

Authors:  Rino Rappuoli
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

Review 5.  Using viruses as nanomedicines.

Authors:  H E van Kan-Davelaar; J C M van Hest; J J L M Cornelissen; M S T Koay
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

Review 6.  The contribution of vaccination to global health: past, present and future.

Authors:  Brian Greenwood
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

7.  Lifestyle Vaccines and Public Health: Exploring Policy Options for a Vaccine to Stop Smoking.

Authors:  Anna Wolters; Guido de Wert; Onno C P van Schayck; Klasien Horstman
Journal:  Public Health Ethics       Date:  2016-03-14       Impact factor: 1.940

8.  Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.

Authors:  Zhaojun Yin; Xuanjun Wu; Katarzyna Kaczanowska; Suttipun Sungsuwan; Marta Comellas Aragones; Christian Pett; Jin Yu; Claire Baniel; Ulrika Westerlind; M G Finn; Xuefei Huang
Journal:  ACS Chem Biol       Date:  2018-05-30       Impact factor: 5.100

9.  Retinoic Acid-Loaded Poly(lactic-co-glycolic acid) Nanoparticle Formulation of ApoB-100-Derived Peptide 210 Attenuates Atherosclerosis.

Authors:  Xianwen Yi; Ying Wang; Zhenquan Jia; Sylvia Hiller; Jun Nakamura; J Christopher Luft; Shaomin Tian; Joseph M DeSimone
Journal:  J Biomed Nanotechnol       Date:  2020-04-01       Impact factor: 4.099

Review 10.  Particle-based platforms for malaria vaccines.

Authors:  Yimin Wu; David L Narum; Sylvain Fleury; Gary Jennings; Anjali Yadava
Journal:  Vaccine       Date:  2015-10-11       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.